Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR -mutated nonsmall cell lung cancer.
Rolof G P GijtenbeekVincent van den NoortJoachim G J V AertsJeske A Staal-van den BrekelEgbert F SmitFrans H KrouwelsFrank A WilschutThijo Jeroen N HiltermannHidde J HaismaEd SchuuringJoost D J JanssenMartijn GoosensPaul M van den BergA Joop de LangenJos A StigtBen E E M van den BorneHarry J M GroenWouter H Van GeffenAnthonie J van der WekkenPublished in: ERJ open research (2022)
-mutated NSCLC at the expense of more toxicity.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- tyrosine kinase
- small cell lung cancer
- single cell
- study protocol
- cell therapy
- chronic myeloid leukemia
- oxidative stress
- locally advanced
- randomized controlled trial
- stem cells
- clinical trial
- squamous cell carcinoma
- brain metastases
- radiation therapy
- mesenchymal stem cells
- chemotherapy induced
- rectal cancer